Efficacy and safety of naftifine HCl gel 2% in the treatment of interdigital and moccasin type tinea pedis: Pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials

Journal of Drugs in Dermatology

Volumn 12, Issue 8, 2013, Pages 911-918

  Gold, Linda F Stein ^a   Parish, Lawrence Charles ^b,c   Vlahovic, Tracey ^d   Kircik, Leon ^e   Plaum, Stefan ^f   Fleischer Jr, Alan B ^f   Verma, Amit ^f   Olayinka, Babajide ^f   Hardas, Bhushan ^f  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Paddington Testing Company Inc   (United States)

^d TEMPLE UNIVERSITY SCHOOL OF PODIATRIC MEDICINE   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f Merz Pharmaceuticals LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAFTIFINE;

ADULT; AGED; APPLICATION SITE DERMATITIS; APPLICATION SITE EROSION; APPLICATION SITE FISSURE; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE REACTION; APPLICATION SITE VESICLE; ARTICLE; BRONCHITIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERSENSITIVITY; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT; TINEA PEDIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ALLYLAMINE; ANTIFUNGAL AGENTS; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TINEA PEDIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84882358761     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. th ed. Philadelphia (PA): Mosby (An affiliate of Elsevier); 2004:409-456.
2. Panackal AA, Halpern EF, Watson AJ. Cutaneous fungal infection in the United States: Analysis of the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), 1995-2004. Int J Dermatol. 2009;48(7):704-12.
3. Hasan M, Fitzgerald M, Saoudian M, et al. Dermatology for the practicing allergist: Tinea pedis and its complication. Clin Mol Allergy. 2004;2:5.
4. Weinstein A, Berman B. Topical treatment of common superficial tinea infection. Amer Fam Phys. 2002;65(10):2095-2103.
5. Evans EG, James IG, Seaman RA, et al. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol. 1993;129 (4):437-442.
6. Merz Pharmaceuticals, LLC. Naftifine product monograph. 2010.
7. Monk JP, Brogden RN. Naftifine: a review of its antimicrobial activity and therapeutic use as in superficial dermatomycoses. Drugs. 1991;42(4):659-72.
8. Vago T, Baldi G, Columbo D, et al. Effects of naftifine, terbinafine, two allylamine antifungal drugs, on selected functions of polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1994;38(11):2605-11.
9. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol. 1996;35(8):591-93.
10. Dobson RL, Hickman JG, Katz HI, et al. Once-daily naftifine cream 1% (Naftin Ò) in the treatment of tinea pedis. Clin Trials J. 1989;26(6):418-23.
11. Kagawa S. Comparative clinical trial of naftifine and clotrimazole in tinea pedis, tinea cruris, and tinea corporis. Mykosen. 1987;30(Suppl 1):63-69.
12. Naftifine Gel Study Group: Naftifine gel in the treatment of tinea pedis: two double-blind, multicenter studies. Cutis. 1991;48(1):85-88.
13. Naftifine Podiatric Study Group. Naftifine cream 1% versus clotrimazole cream 1% in the treatment of tinea pedis. J Am Podiatr Med Assoc. 1990;80(6):314-18.
14. Schachner L, Bagatell F, Whittington C, et al. The safety and efficacy of naftifine 1% in the treatment of tinea pedis. Adv Ther. 1990;7(3):148-52.
15. Smith EB, Berneman DL, Griffith RF, et al. Double-blind comparison of naftifine 1% cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis. J Am Acad Dermatol. 1992;26(1):125-27.
16. Smith EB, Wiss K, Hanifin JM, et al. Comparison of once-and twice-daily naftifine cream regimens with twice-daily clotrimazole in the treatment of tinea pedis. J Am Acad Dermatol. 1990;22 (6 pt 1):1116-7.
17. Stoughton RB, Sefton J, Zeleznik L. In vitro and in vivo cutaneous penetration of and antifungal activity of naftifine. Cutis. 1989;44(4):333-35.
18. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehiclecontrolled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. 2011;10(11):1282-88.
19. Noble SL, Forbes RC, Stamm PL. Diagnosis and management of common tinea infections. Am Fam Physician. 1998;58(1): 163-174.
20. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800-02.
21. Andrews MD, Burns M. Common tinea infections in children. Am Fam Physician. 2008;77(10):1415-20.
22. Masri-Fridling GD. Dermatophytosis of the Feet. Dermatol Clin. 1996;14(1):33-40.
23. Markova T. Clinical Inquiries. What is the Most Effective Treatment for Tinea Pedis (athlete's foot)? J Fam Pract. 2002;51(1):21-7.
24. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehiclecontrolled study evaluating the efficacy and safety of naftifine cream, 2% in tinea cruris. J Drugs Dermatol. 2011;10(10):1142-48.
25. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296- 1310.
26. Joseph WS. A closer look at topical for tinea pedis. Podiatry Today. 2009;22(9):48-56.
27. Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: Improving adherence to topical therapy. J Am Acad Dermatol. 2008;59:1009-1016.
28. Lee IA, Maibach HI. Pharmionics in dermatology. A review of topical medication adherence. Am J Clin Dermatol. 2006;7:231-236.
29. Feldman SR. Practical ways to improve patients' treatment outcomes. Medical Quality Enhancement Corp. 2009.